KristensenSL, RørthR, JhundPS, et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol, 2019; 7: 776–785.
2.
AnkerSD, ButlerJ, FilippatosGS, et al.EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail, 2019; 21: 1279–1287.
3.
BeckRW, RiddlesworthTD, RuedyK, et al.Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: A randomized trial. Ann Intern Med, 2017; 167: 365–374.
4.
KarterAJ, ParkerMM, MoffetHH, GilliamLK, DlottR. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA, 2021; 325: 2273–2284.
5.
MartensT, BeckRW, BaileyR, et al.Effect of continuous glucose monitoring on glycemic control in patients wit type 2 diabetes treated with basal insulin: A randomized clinical trial. JAMA, 2021; 325: 2262–2272.
6.
KrugerDF, EdelmanSV, HinnenDA, ParkinCG. Reference guide for integrating continuous glucose monitoring into clinical practice. Diabetes Educ, 2019; 45(1_suppl): 3S–20S.
7.
BeckRW, BergenstalRM. Beyond A1C-standardization of continuous glucose monitoring reporting: Why it is needed and how it continues to evolve. Diabetes Spectr, 2021; 34: 102–108.
8.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42: 1593–1603.
